 and note k commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report intellectual property litigation is expensive complex and lengthy and its outcome is difficult to predict adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins financial condition results of operation or liquidity pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel in the event that our right to market any of our products is successfully challenged we may be required to obtain a license on terms which may not be favorable to us if at all if we fail to obtain a required license or are unable to design around a patent our business financial condition or results of operations could be materially adversely affectedpending and future product liability claims and other litigation including private securities litigation shareholder derivative suits and contract litigation may adversely affect our business reputation and ability to attract and retain customersthe design manufacture and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims many of the medical devices that we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely a number of factors could result in an unsafe condition or injury to or death of a patient with respect to these or other products that we manufacture or sell including physician technique and experience in performing the surgical procedure component failures manufacturing flaws design defects or inadequate disclosure of productrelated risks or productrelated information these factors could result in product liability claims a recall of one or more of our products or a safety alert relating to one or more of our products product liability claims may be brought by individuals or by groups seeking to represent a class we are currently the subject of product liability litigation proceedings and other proceedings described in more detail under item 3 legal proceedings and note k commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report the outcome of litigation particularly class action lawsuits is difficult to assess or quantify plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts including not only actual damages but also punitive damages the magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time in addition the cost to defend against any future litigation may be significant further we maintain an insurance policy providing limited coverage against securities claims and we are substantially selfinsured with respect to product liability claims and fully selfinsured with respect to intellectual property infringement claims the absence of significant thirdparty insurance coverage increases our potential exposure to unanticipated claims and adverse decisions product liability claims securities and commercial litigation and other litigation in the future regardless of the outcome could have a material adverse effect on our financial condition results of operations or liquidityany failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business financial condition and results of operationsas a medical device manufacturer we are required to register with the fda and are subject to periodic inspection by the fda for compliance with its quality system regulation requirements which require manufacturers of medical devices to adhere to certain regulations including testing quality control and documentation procedures in addition the federal medical device reporting regulations require us to provide information to the fda whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or if a malfunction were to occur could cause or contribute to a death or serious injury compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the fda which may result in observations on form 483 and in some cases warning letters that require corrective action in the european community we are required to maintain certain international standards organization iso certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications if we or our manufacturers fail to adhere to quality system regulations or iso requirements this could delay production of our products and lead to fines difficulties in obtaining regulatory clearances recalls enforcement actions including injunctive relief or consent decrees or other consequences which could in turn have a material adverse effect on our financial condition or results of operations28table of contentsinterruption of our manufacturing operations could adversely affect our results of operations and financial conditionour products are designed and manufactured in technology centers around the world either by us or third parties in most cases the manufacturing of our products is concentrated in one or a few locations factors such as a failure to follow specific internal protocols and procedures equipment malfunction environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products in the event of an interruption in manufacturing we may be unable to quickly move to alternate means of producing affected products or to meet customer demand in some instances for example if the interruption is a result of a failure to follow regulatory protocols and procedures we may experience delays in resuming production of affected products due primarily to needs for regulatory approvals as a result we may experience loss of market share which we may be unable to recapture and harm to our reputation which could adversely affect our results of operations and financial conditionwe rely on external manufacturers to supply us with certain materials components and products any disruption in our sources of supply or the price of inventory supplied to us could adversely impact our production efforts and could materially adversely affect our business financial condition or results of operationswe purchase many of the materials and components used in manufacturing our products some of which are custom made from thirdparty vendors certain supplies are purchased from singlesources due to quality considerations expertise costs or constraints resulting from regulatory requirements in the event of a disruption in supply we may not be able to establish additional or replacement suppliers for certain components materials or products in a timely manner largely due to the complex nature of our and many of our suppliers manufacturing processes in addition our products require sterilization prior to sale and we rely on a mix of internal resources and thirdparty vendors to perform this service production issues including capacity constraint the inability to sterilize our products quality issues affecting us or our suppliers an inability to develop and validate alternative sources if required or a significant increase in the price of materials or components could adversely affect our results of operations and financial conditionour share price will fluctuate and accordingly the value of an investment in our common stock may also fluctuatestock markets in general and our common stock in particular have experienced significant price and volume volatility over recent years the market price and trading volume of our common stock may continue to be subject to significant fluctuations due not only to general stock market conditions but also to variability in the prevailing sentiment regarding our operations or business prospects as well as among other things changing investment priorities of our shareholders if we are unable to attract retain and focus key personnel it could have an adverse effect on our business financial condition and results from operations  we constantly monitor the dynamics of the economy the healthcare industry and the markets in which we compete and we continue to assess opportunities to improve operational effectiveness and better align expenses with revenues while preserving our ability to make needed investments research and development projects capital and our people that we believe are essential to our longterm success in our industry there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees particularly in emerging markets as the trend toward globalization continues if we are unable to attract key personnel in a timely manner including key sales and other personnel who have critical industry experience and relationships in the regions in which we operate including in emerging markets such as brazil russia india and china it may have an adverse effect on our business and our ability to drive growth including through execution of our strategic initiatives furthermore some of the key personnel for whom we compete have postemployment arrangements with their current or former employer that may impact our ability to hire them or expose us and them to claims in addition if we are unable to retain and focus our existing key personnel it may have an adverse effect on our business financial condition and results from operations moreover we recently completed changes in our senior management structure which may lead to inefficiencies and have an adverse effect on our business and results of operations29table of contentsitem 1b unresolved staff commentsnoneitem 2 propertiesour world headquarters are located in natick massachusetts with additional support provided from regional headquarters located in singapore and paris france on november 8 2012 we announced that we are consolidating our natick massachusetts headquarters into our marlborough massachusetts location where we expect to establish a new global headquarters campus as of december 31 2012 our principal manufacturing and technology centers were located in minnesota california and indiana within the us as well as internationally in ireland costa rica and puerto rico our products are distributed worldwide from customer fulfillment centers in massachusetts the netherlands and japan as of december 31 2012 we maintained 12 major manufacturing facilities including six in the us three in ireland two in costa rica and one in puerto rico as well as various distribution and technology centers around the world many of these facilities produce and manufacture products for more than one of our divisions and include research facilities the following is a summary of our facilities as of december 31 2012 in approximate square feet  owned leased totalus 4739000 1329000 6068000international 1512000 1227000 2739000  6251000 2556000 8807000we regularly evaluate the condition and capacity of our facilities to ensure they are suitable for the development manufacturing and marketing of our products and provide adequate capacity for current and expected future needsitem 3 legal proceedingssee note k  commitments and contingencies to our 2012 consolidated financial statements included in item 8 of this annual report and incorporated herein by reference